25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Agios Pharm
Buy, Hold or Sell?

Let's analyze Agios together

I guess you are interested in Agios Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Agios Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Agios Pharm

I send you an email if I find something interesting about Agios Pharm.

1. Quick Overview

1.1. Quick analysis of Agios (30 sec.)










1.2. What can you expect buying and holding a share of Agios? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$27.84
Expected worth in 1 year
$40.13
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$12.29
Return On Investment
25.3%

For what price can you sell your share?

Current Price per Share
$48.64
Expected price per share
$39.94 - $62.58
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Agios (5 min.)




Live pricePrice per Share (EOD)
$48.64
Intrinsic Value Per Share
$-57.12 - $-36.23
Total Value Per Share
$-29.28 - $-8.39

2.2. Growth of Agios (5 min.)




Is Agios growing?

Current yearPrevious yearGrowGrow %
How rich?$1.6b$997.1m-$36.5m-3.8%

How much money is Agios making?

Current yearPrevious yearGrowGrow %
Making money$168.5m-$18.5m$187.1m111.0%
Net Profit Margin1,778.1%59.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Agios (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Agios?

Welcome investor! Agios's management wants to use your money to grow the business. In return you get a share of Agios.

First you should know what it really means to hold a share of Agios. And how you can make/lose money.

Speculation

The Price per Share of Agios is $48.64. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Agios.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Agios, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $27.84. Based on the TTM, the Book Value Change Per Share is $3.07 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.72 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Agios.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps16.2233.4%2.865.9%-0.96-2.0%0.941.9%-0.10-0.2%
Usd Book Value Change Per Share16.2633.4%3.076.3%-0.72-1.5%1.012.1%0.601.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share16.2633.4%3.076.3%-0.72-1.5%1.012.1%0.601.2%
Usd Price Per Share44.43-34.77-26.03-36.18-50.66-
Price to Earnings Ratio0.68--3.53--0.44--4.84--17.45-
Price-to-Total Gains Ratio2.73--17.09--7.33--16.68-15.70-
Price to Book Ratio1.60-2.28-1.50-2.69-5.47-
Price-to-Total Gains Ratio2.73--17.09--7.33--16.68-15.70-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share48.64
Number of shares20
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share3.071.01
Usd Total Gains Per Share3.071.01
Gains per Quarter (20 shares)61.4420.21
Gains per Year (20 shares)245.7680.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1024623608171
204924820162152
307377280243233
409839740323314
50122912200404395
60147514660485476
70172017120566557
80196619580647638
90221222040728719
100245824500809800

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%3.037.00.07.5%4.047.01.07.7%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%9.031.00.022.5%13.036.03.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.052.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%9.031.00.022.5%13.036.03.025.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Agios Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--16.2573.072+429%-0.716+104%1.011+1508%0.605+2588%
Book Value Per Share--27.83816.671+67%17.484+59%17.209+62%12.838+117%
Current Ratio--8.99311.048-19%14.158-36%14.602-38%10.870-17%
Debt To Asset Ratio--0.0920.124-26%0.110-17%0.177-48%0.222-59%
Debt To Equity Ratio--0.1020.142-29%0.124-18%0.262-61%0.333-70%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--3435804126.2802608235988.070+32%2264334106.000+52%2976614918.165+15%3537737163.939-3%
Eps--16.2222.856+468%-0.963+106%0.943+1621%-0.098+101%
Ev To Ebitda Ratio---8.355-6.470-23%-5.114-39%-8.167-2%-19.900+138%
Ev To Sales Ratio--95.82278.500+22%98.167-2%infnan%infnan%
Free Cash Flow Per Share---1.448-1.438-1%-1.351-7%-1.412-3%-1.122-23%
Free Cash Flow To Equity Per Share---1.403-1.393-1%-1.330-5%-1.633+16%-0.682-51%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.005-1%
Intrinsic Value_10Y_max---36.233--------
Intrinsic Value_10Y_min---57.116--------
Intrinsic Value_1Y_max---4.371--------
Intrinsic Value_1Y_min---5.729--------
Intrinsic Value_3Y_max---12.569--------
Intrinsic Value_3Y_min---17.311--------
Intrinsic Value_5Y_max---20.087--------
Intrinsic Value_5Y_min---28.910--------
Market Cap2773948928.000+6%2596169126.2801998234238.070+30%1484496106.000+75%2226474818.165+17%2981334438.939-13%
Net Profit Margin--105.74717.781+495%0.599+17548%-114258.049+108149%-57131.490+54127%
Operating Margin---11.619-12.527+8%-16.892+45%-132437.018+1139696%-66221.060+569820%
Operating Ratio--12.46913.489-8%17.690-30%126587.733-100%63299.122-100%
Pb Ratio1.747+9%1.5962.282-30%1.496+7%2.691-41%5.473-71%
Pe Ratio0.750+9%0.685-3.533+616%-0.441+164%-4.843+807%-17.449+2648%
Price Per Share48.640+9%44.43034.765+28%26.030+71%36.178+23%50.658-12%
Price To Free Cash Flow Ratio-8.395-9%-7.669-6.164-20%-4.989-35%-6.758-12%-20.494+167%
Price To Total Gains Ratio2.992+9%2.733-17.088+725%-7.334+368%-16.681+710%15.703-83%
Quick Ratio--14.72518.537-21%28.174-48%24.855-41%18.807-22%
Return On Assets--0.5290.052+926%-0.023+104%0.001+48589%-0.047+109%
Return On Equity--0.5830.052+1014%-0.026+104%-0.016+103%-0.077+113%
Total Gains Per Share--16.2573.072+429%-0.716+104%1.011+1508%0.605+2588%
Usd Book Value--1626672000.000960530750.000+69%997104750.000+63%1031083100.000+58%758966700.000+114%
Usd Book Value Change Per Share--16.2573.072+429%-0.716+104%1.011+1508%0.605+2588%
Usd Book Value Per Share--27.83816.671+67%17.484+59%17.209+62%12.838+117%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--3435804126.2802608235988.070+32%2264334106.000+52%2976614918.165+15%3537737163.939-3%
Usd Eps--16.2222.856+468%-0.963+106%0.943+1621%-0.098+101%
Usd Free Cash Flow---84637000.000-82528500.000-2%-77028750.000-9%-85273800.000+1%-66670750.000-21%
Usd Free Cash Flow Per Share---1.448-1.438-1%-1.351-7%-1.412-3%-1.122-23%
Usd Free Cash Flow To Equity Per Share---1.403-1.393-1%-1.330-5%-1.633+16%-0.682-51%
Usd Market Cap2773948928.000+6%2596169126.2801998234238.070+30%1484496106.000+75%2226474818.165+17%2981334438.939-13%
Usd Price Per Share48.640+9%44.43034.765+28%26.030+71%36.178+23%50.658-12%
Usd Profit--947915000.000168577000.000+462%-18582250.000+102%76409750.000+1141%5387700.000+17494%
Usd Revenue--8964000.0008217750.000+9%6007500.000+49%19211152.071-53%18693501.035-52%
Usd Total Gains Per Share--16.2573.072+429%-0.716+104%1.011+1508%0.605+2588%
 EOD+5 -3MRQTTM+27 -10YOY+25 -125Y+28 -810Y+20 -17

3.3 Fundamental Score

Let's check the fundamental score of Agios Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.750
Price to Book Ratio (EOD)Between0-11.747
Net Profit Margin (MRQ)Greater than0105.747
Operating Margin (MRQ)Greater than0-11.619
Quick Ratio (MRQ)Greater than114.725
Current Ratio (MRQ)Greater than18.993
Debt to Asset Ratio (MRQ)Less than10.092
Debt to Equity Ratio (MRQ)Less than10.102
Return on Equity (MRQ)Greater than0.150.583
Return on Assets (MRQ)Greater than0.050.529
Total8/10 (80.0%)

3.4 Technical Score

Let's check the technical score of Agios Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.050
Ma 20Greater thanMa 5057.076
Ma 50Greater thanMa 10049.730
Ma 100Greater thanMa 20047.711
OpenGreater thanClose56.110
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Agios Pharm

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-12-05 11:46:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Agios earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Agios to the Biotechnology industry mean.
  • A Net Profit Margin of 10,574.7% means that $105.75 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Agios Pharm:

  • The MRQ is 10,574.7%. The company is making a huge profit. +2
  • The TTM is 1,778.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ10,574.7%TTM1,778.1%+8,796.6%
TTM1,778.1%YOY59.9%+1,718.2%
TTM1,778.1%5Y-11,425,804.9%+11,427,583.0%
5Y-11,425,804.9%10Y-5,713,149.0%-5,712,655.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10,574.7%-109.4%+10,684.1%
TTM1,778.1%-221.4%+1,999.5%
YOY59.9%-208.7%+268.6%
5Y-11,425,804.9%-346.2%-11,425,458.7%
10Y-5,713,149.0%-470.4%-5,712,678.6%
4.3.1.2. Return on Assets

Shows how efficient Agios is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Agios to the Biotechnology industry mean.
  • 52.9% Return on Assets means that Agios generated $0.53 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Agios Pharm:

  • The MRQ is 52.9%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 5.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ52.9%TTM5.2%+47.7%
TTM5.2%YOY-2.3%+7.4%
TTM5.2%5Y0.1%+5.1%
5Y0.1%10Y-4.7%+4.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ52.9%-11.6%+64.5%
TTM5.2%-12.0%+17.2%
YOY-2.3%-11.2%+8.9%
5Y0.1%-12.6%+12.7%
10Y-4.7%-14.2%+9.5%
4.3.1.3. Return on Equity

Shows how efficient Agios is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Agios to the Biotechnology industry mean.
  • 58.3% Return on Equity means Agios generated $0.58 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Agios Pharm:

  • The MRQ is 58.3%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 5.2%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ58.3%TTM5.2%+53.0%
TTM5.2%YOY-2.6%+7.8%
TTM5.2%5Y-1.6%+6.8%
5Y-1.6%10Y-7.7%+6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ58.3%-14.5%+72.8%
TTM5.2%-16.0%+21.2%
YOY-2.6%-14.6%+12.0%
5Y-1.6%-18.6%+17.0%
10Y-7.7%-19.3%+11.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Agios Pharm.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Agios is operating .

  • Measures how much profit Agios makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Agios to the Biotechnology industry mean.
  • An Operating Margin of -1,161.9% means the company generated $-11.62  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Agios Pharm:

  • The MRQ is -1,161.9%. The company is operating very inefficient. -2
  • The TTM is -1,252.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,161.9%TTM-1,252.7%+90.8%
TTM-1,252.7%YOY-1,689.2%+436.5%
TTM-1,252.7%5Y-13,243,701.8%+13,242,449.1%
5Y-13,243,701.8%10Y-6,622,106.0%-6,621,595.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,161.9%-203.3%-958.6%
TTM-1,252.7%-316.3%-936.4%
YOY-1,689.2%-216.5%-1,472.7%
5Y-13,243,701.8%-378.6%-13,243,323.2%
10Y-6,622,106.0%-480.3%-6,621,625.7%
4.3.2.2. Operating Ratio

Measures how efficient Agios is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 12.47 means that the operating costs are $12.47 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Agios Pharm:

  • The MRQ is 12.469. The company is inefficient in keeping operating costs low. -1
  • The TTM is 13.489. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ12.469TTM13.489-1.020
TTM13.489YOY17.690-4.201
TTM13.4895Y126,587.733-126,574.244
5Y126,587.73310Y63,299.122+63,288.612
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.4692.284+10.185
TTM13.4893.198+10.291
YOY17.6903.263+14.427
5Y126,587.7334.651+126,583.082
10Y63,299.1226.419+63,292.703
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Agios Pharm.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Agios is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.99 means the company has $8.99 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Agios Pharm:

  • The MRQ is 8.993. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.048. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.993TTM11.048-2.056
TTM11.048YOY14.158-3.110
TTM11.0485Y14.602-3.553
5Y14.60210Y10.870+3.732
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.9933.601+5.392
TTM11.0483.872+7.176
YOY14.1584.655+9.503
5Y14.6025.973+8.629
10Y10.8706.258+4.612
4.4.3.2. Quick Ratio

Measures if Agios is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Agios to the Biotechnology industry mean.
  • A Quick Ratio of 14.72 means the company can pay off $14.72 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Agios Pharm:

  • The MRQ is 14.725. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 18.537. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.725TTM18.537-3.812
TTM18.537YOY28.174-9.637
TTM18.5375Y24.855-6.318
5Y24.85510Y18.807+6.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.7253.093+11.632
TTM18.5373.416+15.121
YOY28.1744.393+23.781
5Y24.8555.954+18.901
10Y18.8076.436+12.371
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Agios Pharm.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Agios assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Agios to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.09 means that Agios assets are financed with 9.2% credit (debt) and the remaining percentage (100% - 9.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Agios Pharm:

  • The MRQ is 0.092. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.124. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.092TTM0.124-0.032
TTM0.124YOY0.110+0.014
TTM0.1245Y0.177-0.052
5Y0.17710Y0.222-0.046
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0920.345-0.253
TTM0.1240.346-0.222
YOY0.1100.311-0.201
5Y0.1770.365-0.188
10Y0.2220.382-0.160
4.5.4.2. Debt to Equity Ratio

Measures if Agios is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Agios to the Biotechnology industry mean.
  • A Debt to Equity ratio of 10.2% means that company has $0.10 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Agios Pharm:

  • The MRQ is 0.102. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.142. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.102TTM0.142-0.041
TTM0.142YOY0.124+0.018
TTM0.1425Y0.262-0.120
5Y0.26210Y0.333-0.071
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1020.393-0.291
TTM0.1420.431-0.289
YOY0.1240.384-0.260
5Y0.2620.452-0.190
10Y0.3330.497-0.164
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Agios generates.

  • Above 15 is considered overpriced but always compare Agios to the Biotechnology industry mean.
  • A PE ratio of 0.68 means the investor is paying $0.68 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Agios Pharm:

  • The EOD is 0.750. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.685. Based on the earnings, the company is cheap. +2
  • The TTM is -3.533. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.750MRQ0.685+0.065
MRQ0.685TTM-3.533+4.218
TTM-3.533YOY-0.441-3.092
TTM-3.5335Y-4.843+1.310
5Y-4.84310Y-17.449+12.606
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.750-2.259+3.009
MRQ0.685-2.480+3.165
TTM-3.533-3.148-0.385
YOY-0.441-3.244+2.803
5Y-4.843-5.991+1.148
10Y-17.449-6.692-10.757
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Agios Pharm:

  • The EOD is -8.395. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.669. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.164. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.395MRQ-7.669-0.727
MRQ-7.669TTM-6.164-1.505
TTM-6.164YOY-4.989-1.175
TTM-6.1645Y-6.758+0.594
5Y-6.75810Y-20.494+13.736
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.395-2.995-5.400
MRQ-7.669-3.289-4.380
TTM-6.164-3.668-2.496
YOY-4.989-4.472-0.517
5Y-6.758-8.001+1.243
10Y-20.494-9.190-11.304
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Agios is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.60 means the investor is paying $1.60 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Agios Pharm:

  • The EOD is 1.747. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.596. Based on the equity, the company is underpriced. +1
  • The TTM is 2.282. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.747MRQ1.596+0.151
MRQ1.596TTM2.282-0.686
TTM2.282YOY1.496+0.785
TTM2.2825Y2.691-0.409
5Y2.69110Y5.473-2.782
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.7472.001-0.254
MRQ1.5962.054-0.458
TTM2.2822.385-0.103
YOY1.4962.431-0.935
5Y2.6913.690-0.999
10Y5.4734.307+1.166
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Agios Pharm.

4.8.1. Institutions holding Agios Pharm

Institutions are holding 107.783% of the shares of Agios Pharm.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Farallon Capital Management, L.L.C.9.92611.2307566086663640.1125
2024-09-30Vanguard Group Inc9.72460.00445545982492450.8959
2024-06-30BlackRock Inc8.52010.004748590022009074.3131
2024-09-30Bellevue Group AG6.55082.68913735915-143633-3.7023
2024-09-30T. Rowe Price Associates, Inc.4.96670.01452832512552531.9895
2024-09-30State Street Corp4.08810.0042233143321648410.2359
2024-09-30Armistice Capital, LLC3.871.568322070701279196.1525
2024-09-30JPMorgan Chase & Co3.00370.00581712990-63155-3.5557
2024-09-30Macquarie Group Ltd2.96470.08111690801-38928-2.2505
2024-09-30Dimensional Fund Advisors, Inc.2.73920.01681562183-633902-28.8651
2024-09-30Geode Capital Management, LLC2.38040.0049135753161010.4514
2024-09-30Marshall Wace Asset Management Ltd2.21510.0684126328512955011.4268
2024-09-30Bvf Inc2.08681.5468119010700
2024-09-30Polar Capital Holdings PLC1.7570.2124100203610020360
2024-09-30BNP Paribas Investment Partners SA1.59050.0999907044-4131-0.4534
2024-09-30ArrowMark Colorado Holdings, LLC (ArrowMark Partners)1.54780.5024882731-136626-13.4032
2024-09-30Fisher Asset Management, LLC1.49980.015685532814541620.4837
2024-09-30Vestal Point Capital LP1.33262.56087600007600000
2024-09-30Rock Springs Capital Management LP1.22631.011699389-344872-33.0255
2024-06-30Deutsche Bank AG1.16120.0129662236-5061-0.7584
Total 73.151511.654741718441+1328967+3.2%

4.9.2. Funds holding Agios Pharm

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30BB Biotech AG Ord6.55086.24043735915-137633-3.5532
2024-10-31Vanguard Total Stock Mkt Idx Inv3.11040.00461773857-12595-0.705
2024-11-27iShares Russell 2000 ETF2.77760.11521584059-3304-0.2081
2024-10-31Vanguard Small Cap Index2.50020.0416142587628000.1968
2024-09-30Delaware Small Cap Core I2.41940.80521379776-8551-0.6159
2024-09-30T. Rowe Price Health Sciences2.31910.38021322563-12879-0.9644
2024-11-27SPDR® S&P Biotech ETF1.71980.7752980789-29790-2.9478
2024-10-31Polar Capital Biotech S Inc1.68412.196960418-39582-3.9582
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.48550.0347847202-3267-0.3841
2024-10-31DWS Vermögensbildungsfonds I LD1.41250.228880552725000945.0047
2024-10-31Vanguard Small Cap Growth Index Inv1.3740.096783609-1752-0.2231
2024-09-30JPMorgan Small Cap Growth A1.07420.745961259800
2024-10-31BNP Paribas Health Cr Innovtr Cl Cap1.04811.4778597761-8538-1.4082
2024-09-30Fidelity Small Cap Index1.0080.093574836-3578-0.6186
2024-10-31JPM Global Healthcare C (acc) USD0.98830.607456361900
2024-11-27iShares Russell 2000 Value ETF0.97450.23395557467180.1294
2024-04-15Pictet Biopharmaceutical Mother0.86631.0884494076439769.7703
2024-09-30Vanguard Explorer Inv0.86520.097449342700
2024-09-30T. Rowe Price New Horizons0.84560.1007482236-1520-0.3142
2024-09-30US Small-Cap Growth II Equity Comp0.84560.1007482236-1715-0.3544
Total 35.869215.463120456126+32799+0.2%

5.3. Insider Transactions

Insiders are holding 1.509% of the shares of Agios Pharm.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-09-26Cecilia JonesSELL254249.03
2024-08-08Brian GoffSELL1109142.75
2024-04-10Jacqualyn A FouseSELL779127.55
2024-03-05Brian GoffSELL415632.57
2024-03-05James William BurnsSELL264232.57
2024-03-05Kaye I Foster-cheekSELL30032.21
2024-02-20Theodore James Jr. WashburnSELL50426.63
2024-02-14Sarah GheuensSELL64225.14
2024-01-24Brian GoffSELL763521.64
2024-01-24James William BurnsSELL170821.64
2024-01-24Jacqualyn A FouseSELL1072221.64
2024-01-24Cecilia JonesSELL188621.64
2024-01-09Brian GoffSELL1206622.99
2024-01-09Jacqualyn A FouseSELL839122.99
2024-01-09James William BurnsSELL116322.99
2024-01-05Tsveta MilanovaSELL290222.32
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Accumulated Other Comprehensive Income  -5,8965,455-441-646-1,08742-1,0454,4653,420
Income before Tax  -91,324-4,616-95,94014,391-81,549-14,569-96,1181,097,1531,001,035
Net Income  -91,324-4,616-95,94014,391-81,549-14,569-96,1181,044,033947,915
Net Income from Continuing Operations  -91,324-4,616-95,94014,391-81,549-14,569-96,1181,044,033947,915



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets1,791,794
Total Liabilities165,122
Total Stockholder Equity1,626,672
 As reported
Total Liabilities 165,122
Total Stockholder Equity+ 1,626,672
Total Assets = 1,791,794

Assets

Total Assets1,791,794
Total Current Assets1,074,189
Long-term Assets717,605
Total Current Assets
Cash And Cash Equivalents 253,730
Short-term Investments 751,027
Net Receivables 3,118
Inventory 26,429
Other Current Assets 39,885
Total Current Assets  (as reported)1,074,189
Total Current Assets  (calculated)1,074,189
+/-0
Long-term Assets
Property Plant Equipment 57,660
Long Term Investments 655,889
Long-term Assets Other 4,056
Long-term Assets  (as reported)717,605
Long-term Assets  (calculated)717,605
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities119,451
Long-term Liabilities45,671
Total Stockholder Equity1,626,672
Total Current Liabilities
Short-term Debt 16,319
Accounts payable 17,143
Other Current Liabilities 33,307
Total Current Liabilities  (as reported)119,451
Total Current Liabilities  (calculated)66,769
+/- 52,682
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt44,515
Long-term Liabilities Other 1,156
Long-term Liabilities  (as reported)45,671
Long-term Liabilities  (calculated)45,671
+/-0
Total Stockholder Equity
Common Stock73
Retained Earnings -52,401
Accumulated Other Comprehensive Income 3,420
Other Stockholders Equity 1,675,580
Total Stockholder Equity (as reported)1,626,672
Total Stockholder Equity (calculated)1,626,672
+/-0
Other
Capital Stock73
Cash and Short Term Investments 1,004,757
Common Stock Shares Outstanding 58,433
Current Deferred Revenue52,682
Liabilities and Stockholders Equity 1,791,794
Net Debt -192,896
Net Invested Capital 1,626,672
Net Working Capital 954,738
Property Plant and Equipment Gross 57,660
Short Long Term Debt Total 60,834



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
194,470
0
0
0
137,008
125,853
111,252
219,069
201,205
181,912
272,030
269,608
491,904
474,336
474,383
449,086
420,065
396,117
557,601
672,042
619,094
557,316
760,600
687,200
614,397
1,040,126
998,235
929,079
858,457
822,131
783,870
698,616
890,741
799,738
976,141
908,449
852,952
2,488,434
1,874,603
1,541,498
1,437,736
1,335,859
1,252,467
1,180,320
1,238,718
1,151,298
1,085,153
1,007,258
937,118
849,709
773,063
1,791,794
1,791,794773,063849,709937,1181,007,2581,085,1531,151,2981,238,7181,180,3201,252,4671,335,8591,437,7361,541,4981,874,6032,488,434852,952908,449976,141799,738890,741698,616783,870822,131858,457929,079998,2351,040,126614,397687,200760,600557,316619,094672,042557,601396,117420,065449,086474,383474,336491,904269,608272,030181,912201,205219,069111,252125,853137,008000194,470
   > Total Current Assets 
0
0
0
0
130,144
118,347
102,533
198,818
169,747
172,417
245,163
247,560
359,546
364,141
390,152
371,660
337,329
329,469
484,159
600,943
559,892
506,866
604,681
528,307
445,261
802,993
753,782
695,542
613,780
557,095
533,705
490,144
611,704
587,274
846,355
669,086
636,677
2,355,114
1,702,562
1,305,285
1,064,231
975,145
870,007
784,935
832,772
791,656
757,239
704,352
833,835
663,627
632,127
1,074,189
1,074,189632,127663,627833,835704,352757,239791,656832,772784,935870,007975,1451,064,2311,305,2851,702,5622,355,114636,677669,086846,355587,274611,704490,144533,705557,095613,780695,542753,782802,993445,261528,307604,681506,866559,892600,943484,159329,469337,329371,660390,152364,141359,546247,560245,163172,417169,747198,818102,533118,347130,1440000
       Cash And Cash Equivalents 
117,661
0
0
0
91,297
83,377
77,481
106,011
71,560
32,837
108,247
70,049
14,031
439,964
434,037
407,986
375,907
355,754
512,295
285,502
573,564
200,278
138,717
132,741
567,750
994,747
210,323
156,478
805,421
103,443
83,580
81,709
80,931
89,093
295,858
104,855
127,436
1,888,025
969,124
400,224
203,126
80,026
88,543
122,449
139,259
104,139
84,753
64,333
88,205
118,764
84,518
253,730
253,73084,518118,76488,20564,33384,753104,139139,259122,44988,54380,026203,126400,224969,1241,888,025127,436104,855295,85889,09380,93181,70983,580103,443805,421156,478210,323994,747567,750132,741138,717200,278573,564285,502512,295355,754375,907407,986434,037439,96414,03170,049108,24732,83771,560106,01177,48183,37791,297000117,661
       Short-term Investments 
61,507
0
0
0
36,679
32,374
21,794
88,945
95,209
129,432
130,233
149,921
328,034
309,450
297,261
272,317
245,238
273,859
231,321
293,595
380,560
279,480
447,325
375,187
321,212
417,981
506,582
513,414
514,800
421,114
411,810
370,188
483,946
439,528
494,270
500,684
445,493
447,578
703,864
865,833
816,892
843,503
730,766
605,231
643,860
635,062
617,813
583,155
688,723
479,227
485,374
751,027
751,027485,374479,227688,723583,155617,813635,062643,860605,231730,766843,503816,892865,833703,864447,578445,493500,684494,270439,528483,946370,188411,810421,114514,800513,414506,582417,981321,212375,187447,325279,480380,560293,595231,321273,859245,238272,317297,261309,450328,034149,921130,233129,43295,20988,94521,79432,37436,67900061,507
       Net Receivables 
0
0
0
0
0
0
1,247
1,246
476
7,115
3,841
22,600
12,667
13,923
15,756
12,070
11,599
7,385
9,867
11,569
8,314
14,717
5,621
5,063
3,839
4,929
21,339
8,329
10,442
10,514
14,593
12,413
15,319
19,723
18,037
23,315
25,399
0
8,131
6,990
4,378
5,905
4,302
5,592
2,206
1,778
2,251
1,176
2,810
3,453
3,762
3,118
3,1183,7623,4532,8101,1762,2511,7782,2065,5924,3025,9054,3786,9908,131025,39923,31518,03719,72315,31912,41314,59310,51410,4428,32921,3394,9293,8395,0635,62114,7178,31411,5699,8677,38511,59912,07015,75613,92312,66722,6003,8417,1154761,2461,247000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
-95,258
-64,243
-55,621
-58,905
-42,860
-46,926
0
-32,250
0
0
0
-143,814
-212,297
0
863
869
2,328
4,659
5,849
7,331
9,778
11,231
11,371
14,698
0
0
0
16,190
2,485
4,060
5,176
8,492
11,374
15,671
17,274
19,076
23,070
23,937
26,429
26,42923,93723,07019,07617,27415,67111,3748,4925,1764,0602,48516,19000014,69811,37111,2319,7787,3315,8494,6592,3288698630-212,297-143,814000-32,2500-46,926-42,860-58,905-55,621-64,243-95,2580000000000000
   > Long-term Assets 
0
0
0
0
6,864
7,506
8,719
20,251
31,458
9,495
26,867
22,048
132,358
110,195
84,231
77,426
82,736
66,648
73,442
71,099
59,202
50,450
155,919
158,893
169,136
237,133
244,453
233,537
244,677
265,036
250,165
208,472
279,037
212,464
129,786
239,363
216,275
133,320
172,041
236,213
373,505
360,714
382,460
395,385
405,946
359,642
327,914
302,906
103,283
186,082
140,936
717,605
717,605140,936186,082103,283302,906327,914359,642405,946395,385382,460360,714373,505236,213172,041133,320216,275239,363129,786212,464279,037208,472250,165265,036244,677233,537244,453237,133169,136158,893155,91950,45059,20271,09973,44266,64882,73677,42684,231110,195132,35822,04826,8679,49531,45820,2518,7197,5066,8640000
       Property Plant Equipment 
3,222
0
0
0
3,565
4,092
3,818
3,551
3,758
3,452
3,210
3,677
6,386
14,297
19,328
21,127
23,220
22,950
25,134
26,261
25,337
24,139
24,771
24,019
24,431
23,732
24,134
24,613
24,320
81,742
121,516
119,893
126,108
126,161
123,926
121,124
117,542
111,722
107,828
103,174
104,230
101,978
97,660
93,130
88,116
83,959
79,500
73,947
69,791
65,725
61,476
57,660
57,66061,47665,72569,79173,94779,50083,95988,11693,13097,660101,978104,230103,174107,828111,722117,542121,124123,926126,161126,108119,893121,51681,74224,32024,61324,13423,73224,43124,01924,77124,13925,33726,26125,13422,95023,22021,12719,32814,2976,3863,6773,2103,4523,7583,5513,8184,0923,5650003,222
       Long Term Investments 
0
0
0
0
0
0
0
13,412
27,125
5,005
22,631
17,917
125,382
95,258
64,243
55,621
58,905
42,860
46,926
43,499
32,250
23,423
129,899
133,804
143,814
212,297
219,724
208,508
220,119
183,234
128,649
88,579
152,929
84,503
4,285
116,889
97,608
21,598
61,313
130,139
266,375
255,836
280,845
298,352
313,874
271,727
244,357
224,902
29,435
116,301
75,404
655,889
655,88975,404116,30129,435224,902244,357271,727313,874298,352280,845255,836266,375130,13961,31321,59897,608116,8894,28584,503152,92988,579128,649183,234220,119208,508219,724212,297143,814133,804129,89923,42332,25043,49946,92642,86058,90555,62164,24395,258125,38217,91722,6315,00527,12513,4120000000
       Long-term Assets Other 
0
0
0
0
593
708
2,195
582
575
1,038
1,026
454
590
640
660
678
611
838
1,382
1,339
1,615
2,888
1,249
1,070
891
1,104
595
416
238
60
98,500
95,833
94,636
1,800
1,575
1,350
1,125
0
2,900
2,900
2,900
2,900
3,955
3,903
3,956
3,956
4,057
4,057
4,057
4,056
4,056
4,056
4,0564,0564,0564,0574,0574,0573,9563,9563,9033,9552,9002,9002,9002,90001,1251,3501,5751,80094,63695,83398,500602384165951,1048911,0701,2492,8881,6151,3391,3828386116786606405904541,0261,0385755822,1957085930000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
2,706
2,706
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000002,7062,706000000
> Total Liabilities 
131,330
0
0
0
93,110
88,733
82,380
76,474
69,723
60,569
71,482
61,859
67,538
47,519
70,218
73,429
74,947
63,744
268,523
270,593
260,503
249,936
251,608
237,394
238,894
174,532
175,093
168,866
170,920
201,874
251,193
250,325
250,213
174,439
417,676
427,997
453,452
191,804
152,787
146,736
145,761
128,406
128,397
130,150
137,904
114,772
120,917
120,415
126,099
105,787
112,553
165,122
165,122112,553105,787126,099120,415120,917114,772137,904130,150128,397128,406145,761146,736152,787191,804453,452427,997417,676174,439250,213250,325251,193201,874170,920168,866175,093174,532238,894237,394251,608249,936260,503270,593268,52363,74474,94773,42970,21847,51967,53861,85971,48260,56969,72376,47482,38088,73393,110000131,330
   > Total Current Liabilities 
48,158
0
0
0
35,113
37,031
36,979
37,377
36,930
34,081
44,638
35,084
61,089
36,379
45,198
49,756
52,888
45,055
67,264
78,003
88,433
82,429
93,648
88,112
94,941
74,699
84,870
84,746
93,503
80,907
89,504
92,432
92,886
69,858
64,353
69,771
94,394
96,504
60,649
57,896
59,826
45,792
48,396
53,596
62,629
45,113
55,141
58,425
67,955
51,691
62,637
119,451
119,45162,63751,69167,95558,42555,14145,11362,62953,59648,39645,79259,82657,89660,64996,50494,39469,77164,35369,85892,88692,43289,50480,90793,50384,74684,87074,69994,94188,11293,64882,42988,43378,00367,26445,05552,88849,75645,19836,37961,08935,08444,63834,08136,93037,37736,97937,03135,11300048,158
       Short-term Debt 
0
0
0
0
6,668
7,171
8,831
10,021
8,171
3,974
5,598
10,004
14,330
16,716
9,389
6,240
4,699
1,949
183,540
0
154,297
0
0
0
125,798
81,831
0
0
59,809
9,128
6,397
7,298
6,915
6,772
6,981
7,194
7,410
8,309
9,771
10,295
11,159
11,994
12,223
13,425
13,663
13,992
14,326
14,664
30,016
15,407
31,720
16,319
16,31931,72015,40730,01614,66414,32613,99213,66313,42512,22311,99411,15910,2959,7718,3097,4107,1946,9816,7726,9157,2986,3979,12859,8090081,831125,798000154,2970183,5401,9494,6996,2409,38916,71614,33010,0045,5983,9748,17110,0218,8317,1716,6680000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,128
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000009,12800000000000000000000000000000
       Accounts payable 
3,573
0
0
0
3,308
4,737
3,038
2,140
3,678
4,411
5,388
6,225
11,067
12,640
8,914
8,971
14,748
13,746
18,448
15,424
17,106
16,152
23,409
17,899
22,767
17,932
17,320
16,616
17,880
12,413
15,435
21,511
21,896
18,707
15,461
12,853
26,844
51,224
7,654
10,308
16,700
11,551
7,790
10,415
18,616
8,662
11,626
13,271
9,780
11,155
10,035
17,143
17,14310,03511,1559,78013,27111,6268,66218,61610,4157,79011,55116,70010,3087,65451,22426,84412,85315,46118,70721,89621,51115,43512,41317,88016,61617,32017,93222,76717,89923,40916,15217,10615,42418,44813,74614,7488,9718,91412,64011,0676,2255,3884,4113,6782,1403,0384,7373,3080003,573
       Other Current Liabilities 
26,718
0
0
0
6,733
7,222
8,869
10,165
8,180
4,598
5,606
10,012
14,336
16,720
4,287
11,895
13,776
12,837
-166,193
26,164
-118,883
28,587
33,170
34,346
-91,466
-64,276
26,418
25,989
-16,896
74,398
98,436
93,500
106,284
79,262
41,911
49,724
60,140
36,971
43,224
37,293
31,967
19,747
28,383
29,756
30,350
22,459
29,189
30,490
28,159
25,129
20,882
33,307
33,30720,88225,12928,15930,49029,18922,45930,35029,75628,38319,74731,96737,29343,22436,97160,14049,72441,91179,262106,28493,50098,43674,398-16,89625,98926,418-64,276-91,46634,34633,17028,587-118,88326,164-166,19312,83713,77611,8954,28716,72014,33610,0125,6064,5988,18010,1658,8697,2226,73300026,718
   > Long-term Liabilities 
0
0
0
0
57,997
51,702
45,401
39,097
32,793
26,488
26,844
26,775
6,449
11,140
25,020
23,673
22,059
18,689
201,259
192,590
172,070
167,507
157,960
149,282
143,953
99,833
90,223
84,120
77,417
120,967
161,689
157,893
157,327
104,581
353,323
358,226
359,058
95,300
92,138
88,840
85,935
82,614
80,001
76,554
75,275
69,659
65,776
61,990
58,144
54,096
49,916
45,671
45,67149,91654,09658,14461,99065,77669,65975,27576,55480,00182,61485,93588,84092,13895,300359,058358,226353,323104,581157,327157,893161,689120,96777,41784,12090,22399,833143,953149,282157,960167,507172,070192,590201,25918,68922,05923,67325,02011,1406,44926,77526,84426,48832,79339,09745,40151,70257,9970000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
673
571
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000057167300000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-6,668
-7,171
-8,831
-10,021
-8,171
-3,974
-5,598
-10,004
-14,330
-16,716
-9,389
-6,240
-4,699
-1,949
-183,540
0
-154,297
0
0
0
-125,798
-81,831
0
0
-59,809
66,006
110,073
108,096
106,747
104,581
102,365
100,105
97,789
95,300
92,138
88,840
85,935
82,614
78,946
75,499
71,996
68,346
64,620
60,834
41,980
52,940
32,900
44,515
44,51532,90052,94041,98060,83464,62068,34671,99675,49978,94682,61485,93588,84092,13895,30097,789100,105102,365104,581106,747108,096110,07366,006-59,80900-81,831-125,798000-154,2970-183,540-1,949-4,699-6,240-9,389-16,716-14,330-10,004-5,598-3,974-8,171-10,021-8,831-7,171-6,6680000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
2,706
2,706
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000002,7062,706000000
       Long-term Liabilities Other 
0
0
0
0
0
0
10
262
6
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,294
59,809
0
0
0
157,327
0
250,958
258,121
359,058
0
92,138
88,840
85,935
82,614
80,001
76,554
3,279
69,659
65,776
1,156
1,156
1,156
1,156
1,156
1,1561,1561,1561,1561,15665,77669,6593,27976,55480,00182,61485,93588,84092,1380359,058258,121250,9580157,32700059,80966,294000000000000000023626210000000
       Deferred Long Term Liability 
0
0
0
0
0
0
45,103
38,835
32,567
26,485
26,842
26,775
6,449
11,140
25,020
23,673
22,059
18,689
201,259
192,590
172,070
167,507
157,960
149,282
143,953
99,833
90,223
17,826
17,608
0
0
0
0
571
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000571000017,60817,82690,22399,833143,953149,282157,960167,507172,070192,590201,25918,68922,05923,67325,02011,1406,44926,77526,84226,48532,56738,83545,103000000
> Total Stockholder Equity
63,140
0
0
0
43,898
37,120
28,872
142,595
131,482
121,343
200,548
207,749
424,366
426,817
404,165
375,657
345,118
332,373
289,078
401,449
358,591
307,380
508,992
449,806
375,503
865,594
823,142
760,213
687,537
620,257
532,677
448,291
640,528
625,299
558,465
480,452
399,500
2,296,630
1,721,816
1,394,762
1,291,975
1,207,453
1,124,070
1,050,170
1,100,814
1,036,526
964,236
886,843
811,019
743,922
660,510
1,626,672
1,626,672660,510743,922811,019886,843964,2361,036,5261,100,8141,050,1701,124,0701,207,4531,291,9751,394,7621,721,8162,296,630399,500480,452558,465625,299640,528448,291532,677620,257687,537760,213823,142865,594375,503449,806508,992307,380358,591401,449289,078332,373345,118375,657404,165426,817424,366207,749200,548121,343131,482142,59528,87237,12043,89800063,140
   Common Stock
3
0
0
0
3
23
4
31
31
32
34
35
37
37
37
38
38
38
38
42
42
42
48
49
49
58
58
58
58
59
59
59
68
69
69
69
69
70
70
71
71
71
71
71
71
72
72
72
72
73
73
73
73737372727272717171717171707069696969685959595858585849494842424238383838373737353432313142330003
   Retained Earnings Total Equity00000-635,385-551,579-470,561-507,087-425,340-333,534-238,760-144,133-55,3670-1,843,475-1,745,818-1,646,839-1,556,361-1,516,105-1,413,755-1,307,582-1,197,711-1,104,633-1,012,839-918,175-849,430-798,061-709,776-632,639-549,557-483,151-426,665-363,831-307,878-284,680-244,057-203,802-171,905-166,948-140,284-143,988-125,692-113,444-101,062-89,885000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-2
-1
-5
25
14
33
12
51
-57
191
222
225
-318
89
297
29
-313
-212
-650
-515
-1,389
-2,643
-2,398
-2,119
-2,171
-484
490
464
202
74
1,636
663
105
-3
-144
-198
-1,198
-7,745
-10,502
-15,083
-12,535
-8,411
-8,870
-5,896
-441
-1,087
-1,045
3,420
3,420-1,045-1,087-441-5,896-8,870-8,411-12,535-15,083-10,502-7,745-1,198-198-144-31056631,63674202464490-484-2,171-2,119-2,398-2,643-1,389-515-650-212-3132929789-318225222191-575112331425-5-1-20000
   Capital Surplus 
0
0
0
0
0
0
2,836
243,601
244,881
246,970
344,490
347,947
591,334
598,494
607,708
619,451
630,078
640,124
652,574
828,043
842,013
857,107
1,142,233
1,160,048
1,174,904
1,717,609
1,743,657
1,775,113
1,794,283
1,818,393
1,839,710
1,861,523
2,156,363
2,181,517
2,203,599
2,225,538
2,242,801
0
2,306,304
2,322,460
2,334,348
2,351,147
2,362,327
2,374,755
2,386,325
2,398,930
2,410,905
0
0
0
0
0
000002,410,9052,398,9302,386,3252,374,7552,362,3272,351,1472,334,3482,322,4602,306,30402,242,8012,225,5382,203,5992,181,5172,156,3631,861,5231,839,7101,818,3931,794,2831,775,1131,743,6571,717,6091,174,9041,160,0481,142,233857,107842,013828,043652,574640,124630,078619,451607,708598,494591,334347,947344,490246,970244,881243,6012,836000000
   Treasury Stock00000-802,486-802,486-802,486-802,486-802,486-802,486-802,486-783,438-529,04700000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
4,024
118,363
5,672
243,601
244,881
246,970
344,490
347,947
591,334
598,494
607,708
619,451
630,078
640,124
652,574
828,043
842,013
857,107
1,142,233
1,160,048
1,174,904
1,717,609
1,743,657
1,775,113
1,794,283
1,818,393
1,839,710
1,861,523
2,156,363
2,181,517
2,203,599
2,225,538
2,242,801
2,265,713
1,777,257
1,539,022
1,531,862
1,548,661
1,559,841
1,572,269
1,583,839
1,596,444
1,608,419
1,619,376
1,634,037
1,649,134
1,661,798
1,675,580
1,675,5801,661,7981,649,1341,634,0371,619,3761,608,4191,596,4441,583,8391,572,2691,559,8411,548,6611,531,8621,539,0221,777,2572,265,7132,242,8012,225,5382,203,5992,181,5172,156,3631,861,5231,839,7101,818,3931,794,2831,775,1131,743,6571,717,6091,174,9041,160,0481,142,233857,107842,013828,043652,574640,124630,078619,451607,708598,494591,334347,947344,490246,970244,881243,6015,672118,3634,0240000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.